• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics partners to provide veterans with Eversense CGM

February 15, 2019 By Sarah Faulkner

Senseonics - updated logoSenseonics (NYSE:SENS) this week announced that it partnered with Geo-Med to provide access to the Eversense continuous glucose monitor to more than 9 million veterans and U.S. government staff.

The company’s Eversense device is the first CGM system to feature an implantable sensor that can be worn for up to 90 days.

The system includes a small sensor that is implanted just below the skin in an in-office procedure. It continuously measures glucose levels, sending that data to a mobile app every five minutes and alerting users if their glucose levels drop out of range. The company’s wearable transmitter can also be removed, recharged and re-adhered without discarding the implanted sensor.

“We are pleased to partner with Geo-Med in providing veterans with diabetes access to the latest CGM technology available. This agreement gives veterans and Department of Defense personnel at military treatment facilities the ability to choose our Eversense CGM System to help manage their diabetes,” president & CEO Tim Goodnow said in prepared remarks. “Strategic partnerships like this serve to broaden access to Eversense for more patients. Further, consistent with our corporate values, we are proud to partner for growth with Geo-Med, a veteran-owned business.”

“We are proud to partner with companies like Senseonics to offer the latest CGM technology to our veterans,” Geo-Med CEO Mike Locke added. “Being a veteran myself, our mission is to deliver superior customer service, uncompromised product quality and business integrity for our nation’s finest at VA Medical Centers and Military Treatment Facilities all over the country. We are determined to provide the highest level of service to all those who served—past and present. This partnership is another example of us fulfilling our mission.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, Patient Monitoring, Wall Street Beat Tagged With: Senseonics

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS